Press releases

2021-05-13 - 19:06

Genkyotex provides business update and reports cash position at March 31, 2021

2021-02-18 - 19:15

Genkyotex Announces 2020 Annual Financial Results And Provides Corporate Update

2021-01-27 - 10:00

Genkyotex provides Q4 business update and reports cash position

2021-01-22 - 07:00

Genkyotex announces update for near term clinical development plan for setanaxib

2021-01-18 - 08:00

Genkyotex announces positive Phase 1 results demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib

2020-12-08 - 07:00

Genkyotex’s setanaxib granted Orphan Drug Designation by the European Commission for the treatment of PBC

2020-11-03 - 15:15

Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex

2020-10-22 - 18:30

Genkyotex provides business update and reports cash position at September 30, 2020

2020-10-20 - 18:00

Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC

2020-09-17 - 18:00

Genkyotex announces first-half 2020 results and business update

2020-09-14 - 18:00

Genkyotex announces the enrollment of the 1st patient in the Phase 2 trial of setanaxib in idiopathic pulmonary fibrosis (IPF)

2020-08-13 - 07:00

Genkyotex announces agreement for Calliditas Therapeutics to acquire controlling interest in Genkyotex SA

2020-07-23 - 18:02

Genkyotex provides business update and reports cash position at June 30, 2020

2020-06-30 - 17:45

Genkyotex announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib

2020-06-18 - 07:00

Genkyotex provides new clinical data from the PBC Phase 2 trial providing further evidence of the anti-fibrotic activity of setanaxib

2020-05-13 - 18:00

Genkyotex receives approval from the ANSM to initiate a Phase 1 clinical study with high-dose setanaxib

2020-04-23 - 18:00

Genkyotex provides business update and reports cash position at March 31, 2020

2020-03-03 - 18:38

Genkyotex’s setanaxib significantly improves immunotherapy including checkpoint inhibitors in multiple preclinical cancer models

2020-02-27 - 18:00

Genkyotex announces 2019 annual financial results and provides corporate update

2020-02-06 - 20:30

Genkyotex raises €4.9 million in its rights issue

2020-02-04 - 17:45

Genkyotex announces its financial calendar for 2020

2020-01-17 - 07:00

Genkyotex launches a rights issue for a maximum amount of €6.13 million

2020-01-16 - 19:30

Genkyotex provides business update and reports gross cash position at December 31, 2019

2020-01-13 - 17:00

Half-yearly report on Genkyotex’s liquidity contract with Kepler Cheuvreux

2019-12-03 - 07:00

Genkyotex reports progress of Setanaxib phase 2 investigator initiated trials

2019-10-24 - 18:00

Genkyotex provides business update and reports cash position at September 30, 2019

2019-09-19 - 18:00

Genkyotex Announces First Half 2019 Results

2019-08-20 - 17:30

Genkyotex Extends Conversion Period for Outstanding €1.6 Million Convertible Debt by 12 Months

2019-07-25 - 07:00

Genkyotex announces positive post-hoc analysis of PBC phase 2 trial and reports cash position at june 30, 2019

2019-07-22 - 07:00

The WHO recognizes NOX inhibitors as new therapeutic class and approves SETANAXIB for GKT831

2019-07-17 - 07:00

Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

2019-07-01 - 07:00

Genkyotex’s GKT831 prevents multiple complications of portal hypertension in preclinical model

2019-06-24 - 07:00

Final Data Analysis of Phase 2 PBC Trial

2019-06-21 - 17:00

Result of the vote on the resolutions - Combined General Meeting of June 13, 2019 at 10 am (French)

2019-06-18 - 17:00

Registration Document including the Annual Financial Report 2018

2019-05-29 - 12:20

Notice of Meeting - Shareholders' General Meeting of June 13, 2019 (French)

2019-05-23 - 18:00

Genkyotex invites shareholders to annual general meeting on June 13, 2019

2019-05-21 - 07:00

Publication of GKT831 data in the Journal of Hepatology

2019-05-02 - 07:00

Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients

2019-05-01 - 18:00

Genkyotex Conference Call at 2pm Paris time on 2nd MayGenkyotex Conference Call at 2pm Paris time on 2nd May

2019-04-25 - 18:00

Genkyotex provides corporate update and reports cash position at March 31, 2019

2019-04-08 - 07:00

Genkyotex to present updated interim results from Phase 2 trial of GKT831 in primary biliary cholongitis at 2019 EASL International Liver Congress (ILC)

2019-03-29 - 07:00

Genkyotex reverse stock split takes effect

2019-03-11 - 07:00

Genkyotex Announces Completion of 24-Week Treatment Period of its Phase 2 Trial with GKT831 in PBC

2019-02-28 - 19:00

Genkyotex announces 2018 annual financial results and provides corporate update

2019-02-27 - 07:00

Launch of the reverse stock split of Genkyotex shares

2019-02-20 - 18:14

Genkyotex to Present Corporate Overview at Two Upcoming NASH Conferences

2019-02-11 - 19:00

Genkyotex Announces Award of Grant from Cancer Research UK to Academic Partner to Further Develop NOX Research in Oncology

2019-01-31 - 18:00

Genkyotex Provides Corporate Update and Reports Cash Position at December 31, 2018

2019-01-25 - 07:00

Genkyotex announces the approval of reverse stock split by its shareholders and provides business update